ABL Bio Launches Clinical Collaboration to Assess ABL103 with KEYTRUDA in Solid Tumor Patients
ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a…
Read More...
Read More...
